Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

121. Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer 28680962 2018 11 13 2366-1070 5 1 2017 Oncology and therapy Oncol Ther Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer. 119-123 10.1007/s40487-017-0040-8 Luteinizing hormone-releasing hormone (LHRH) analogues are widely used for the treatment of advanced hormone-dependent prostate cancer. However (...) , there are currently no clinical guidelines for switching between LHRH analogues. It has been reported that there may be clinical benefits for patients switching between different formulations of LHRH agonists, as well as from an LHRH agonist to LHRH antagonist, but there are no published data on switching from an LHRH antagonist to an LHRH agonist. In this paper, we summarize the clinical notes of 10 patients with hormone-sensitive advanced prostate cancer who switched from an LHRH antagonist to an LHRH agonist

Oncology and therapy2017 Full Text: Link to full Text with Trip Pro

122. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. BACKGROUND: Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. METHODS: In a double-blind, placebo-controlled (...) trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therapy (24 months

NEJM2017

123. Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer

Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc.. Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives High-intensity focused ultrasound (HIFU) is a minimally invasive (transrectal) treatment that generates heat through sound energy to destroy tumor tissue. Sound waves produced by an ultrasonic transducer mounted on an endorectal probe penetrate the rectal wall and ablate the entire prostate gland or focal

Health Technology Assessment (HTA) Database.2017

124. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer

Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer . Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Prostate cancer is expected to be the most common cancer diagnosed among men in the United States in 2016, comprising nearly

Health Technology Assessment (HTA) Database.2017

125. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer

Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer . Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Prostate cancer is expected to be the most common cancer diagnosed among men in the United States in 2016, comprising nearly

Health Technology Assessment (HTA) Database.2017

126. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer

Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer 27870566 2016 11 21 2017 02 10 1527-7755 35 2 2017 Jan 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. 201-207 Purpose Recent observational studies have associated the use of androgen deprivation therapy (ADT) with an increased risk of dementia and Alzheimer's (...) disease, but these studies had limitations. The objective of this study was to determine whether the use of ADT is associated with an increased risk of dementia, including Alzheimer's disease, in patients with prostate cancer. Patients and Methods Using the United Kingdom's Clinical Practice Research Datalink, we assembled a cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer between April 1, 1988 and April 30, 2015, and observed them until April 30, 2016. Time-dependent Cox

EvidenceUpdates2017

127. Clinical and dosimetric predictors of late rectal bleeding of prostate cancer after TomoTherapy intensity modulated radiation therapy

Clinical and dosimetric predictors of late rectal bleeding of prostate cancer after TomoTherapy intensity modulated radiation therapy 28145071 2018 04 30 2018 11 13 2051-3909 64 3 2017 Sep Journal of medical radiation sciences J Med Radiat Sci Clinical and dosimetric predictors of late rectal bleeding of prostate cancer after TomoTherapy intensity modulated radiation therapy. 172-179 10.1002/jmrs.217 Rectal bleeding after radiotherapy impacts the quality of life of long-term surviving prostate (...) cancer patients. We sought to identify factors associated with late rectal bleeding following intensity modulated radiation therapy (IMRT) using TomoTherapy for prostate cancer. We retrospectively analysed 82 patients with localised prostate cancer treated with TomoTherapy. Most patients (95.1%) received neoadjuvant and concurrent hormone therapy. Forty-two patients (51.2%) graded as high risk using D'Amico's classification underwent radiotherapy involving the pelvic nodal area. Late bleeding

Journal of medical radiation sciences2017 Full Text: Link to full Text with Trip Pro

128. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. BACKGROUND: Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy (...) . METHODS: We did this multicentre, paired-cohort, confirmatory study to test diagnostic accuracy of MP-MRI and TRUS-biopsy against a reference test (template prostate mapping biopsy [TPM-biopsy]). Men with prostate-specific antigen concentrations up to 15 ng/mL, with no previous biopsy, underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy. The conduct and reporting of each test was done blind to other test results. Clinically significant cancer was defined as Gleason score ≥4 + 3

Lancet2017

129. Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center

Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center 28740924 2018 11 13 2452-1094 2 2 2017 Apr-Jun Advances in radiation oncology Adv Radiat Oncol Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center. 132-139 10.1016/j.adro.2017.01.004 Despite increasing use, proton therapy (PT) remains a relatively limited resource. The purpose of this study was to assess clinical (...) and demographic differences in PT use for prostate cancer compared to intensity modulated radiation therapy (IMRT) at a single institution. All patients with low- and intermediate-risk prostate cancer (N = 633) who underwent definitive radiation therapy between 2010 and 2015 were divided into PT (n = 508) and IMRT (n = 125) comparison groups and compared using χ 2 and independent sample t tests. Univariable and multivariable logistic regression analyses were conducted to assess the associations between PT use

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

130. In vitro antioxidant and anticancer activity of Leea indica leaf extracts on human prostate cancer cell lines

In vitro antioxidant and anticancer activity of Leea indica leaf extracts on human prostate cancer cell lines 28462147 2018 11 13 2213-4220 6 1 2017 Mar Integrative medicine research Integr Med Res In vitro antioxidant and anticancer activity of Leea indica leaf extracts on human prostate cancer cell lines. 79-87 10.1016/j.imr.2017.01.004 To determine the phytochemical constituents, antioxidant, and anticancer activities of Leea indica leaf extracts on DU-145 and PC-3 human prostate cancer cell (...) human prostate cancer cell lines was evaluated by (3-(4, 5-dimethyl thiazole-2yl)-2, 5-diphenyl tetrazolium bromide) MTT assay. Phytochemical screening confirmed the presence of phyto-constituents like alkaloids, flavonoids, glycosides, phenols, lignins, saponins, sterols, tannins, anthraquinone, and reducing sugar. Methanol and ethanol extracts exhibited higher phenolic content as compare to aqueous extract. Antioxidant capacities were shown highest in methanol and ethanol extracts based

Integrative medicine research2017 Full Text: Link to full Text with Trip Pro

131. Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App

Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App 28410180 2018 11 13 2369-1999 3 1 2017 Jan 06 JMIR cancer JMIR Cancer Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App. e1 10.2196/cancer.6750 The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need (...) for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both practitioners and patients for a variety of purposes. The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC). The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate

JMIR cancer2017 Full Text: Link to full Text with Trip Pro

132. Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial 27870567 2016 11 21 2017 01 17 1527-7755 35 3 2017 Jan 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. 291-297 10.1200/JCO.2016.68.8788 Purpose Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought (...) to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with advanced PC. Methods Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n = 94) or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological distress, cancer-specific distress, and prostate-specific antigen anxiety. Mindfulness skills were assessed

EvidenceUpdates2017

134. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update.

Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. | National Guideline Clearinghouse success fail JUN Jul 10 2017 2018 2019 03 Oct 2017 - 14 Jun 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue (...) NGC:011222 2017 May 20 NEATS Assessment Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. J Clin Oncol. 2017 May 20;35(15):1737-43. [22 references] This is the current release

National Guideline Clearinghouse (partial archive)2017

135. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline.

Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100 (...) Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011220 2017 Apr NEATS Assessment Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Sanda MG, Chen RC, Crispino T, Freedland S, Greene K

National Guideline Clearinghouse (partial archive)2017

137. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance

In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In localised prostate cancer, radical prostatectomy was associated

Evidence-Based Medicine (Requires free registration)2017

138. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up

Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation

Evidence-Based Medicine (Requires free registration)2017

139. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline American Urological Association - Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline American Urological Association - Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline advertisement Toggle navigation About Us Membership About AUA AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Non-Neoplastic (...) Lesions Cystitis Histoanatomic Abnormalities/Malformations Non-invasive Urothelial Neoplasms Invasive Urothelial Neoplasms Non-urothelial Carcinomas Mesenchymal and Other Tumors Prostate Non-Neoplastic Lesions Putative Precursor Lesions Atypical Diagnosis Adenocarcinoma Other Uncommon Carcinomas Mesenchymal and Other Tumors Kidney Inflammatory/Necrotic Renal Lesions Renal Cystic Diseases Benign Epithelial Tumors Renal Cell Carcinomas Childhood Tumors Mesenchymal and Other Tumors Renal Tumors

American Urological Association2017

140. Second-Line Hormonal Therapy for Men with Chemotherapy-Naïve Castration-Resistant Prostate Cancer PCO

Second-Line Hormonal Therapy for Men with Chemotherapy-Naïve Castration-Resistant Prostate Cancer PCO ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology | |

American Society of Clinical Oncology Guidelines2017